Patient characteristics
| Age | Sex | Body mass index (kg/m²) | Months since rituximab | Overall rituximab treatment duration | Aetiology | GFR (CKD-EPI; mL/min/1.73²) | |
| 1 | 73 | F | 21.5 | 2 | 8 | MPO | 31.7 |
| 2 | 65 | M | 32.2 | 2 | 26 | PR3 | 38.6 |
| 3 | 60 | M | 35.4 | 7 | 26 | IgAV | 17.3 |
| 4 | 57 | M | 23.3 | 6 | 6 | MPO | 47.1 |
| 5 | 74 | M | 32.1 | 7 | 7 | MGN | 45.2 |
| 6 | 79 | M | 25.1 | 5 | 27 | MGN | 43.7 |
| 7 | 52 | F | 25.7 | 4 | 17 | MPO/PR3 | 43.2 |
| 8 | 64 | M | 27.5 | 4 | 21 | PR3 | 27.5 |
| 9 | 64 | F | 34.6 | 4 | 10 | PR3 | 47.9 |
GFR, glomerular filtration rate; IgAV, IgA–associated vasculitis; MGN, membranous glomerulonephritis; MPO, myeloperoxidase; PR3, proteinase 3.